Glaukos Corporation
26061 Merit Circle
Suite 101
Laguna Hills
California
92653
United States
Tel: 949-367-9600
219 articles about Glaukos Corporation
-
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
2/21/2024
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced financial results for the fourth quarter and full year ended December 31, 2023.
-
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
1/31/2024
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024.
-
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
1/9/2024
Glaukos Corporation today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.
-
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference - December 20, 2023
12/20/2023
Glaukos Corporation today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.
-
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
12/14/2023
Glaukos Corporation (NYSE: GKOS) announced today the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).
-
Glaukos Announces Participation in Stifel Healthcare Conference
11/7/2023
Glaukos Corporation announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City.
-
Glaukos Announces Third Quarter 2023 Financial Results
11/1/2023
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023.
-
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
10/31/2023
Glaukos Corporation (NYSE: GKOS) announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA.
-
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
10/11/2023
Glaukos Corporation plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023.
-
Glaukos Announces Participation in Wells Fargo Healthcare Conference - August 23, 2023
8/23/2023
Glaukos Corporation today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA.
-
Glaukos Announces Second Quarter 2023 Financial Results
8/2/2023
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023.
-
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
7/17/2023
Glaukos Corporation announced today that it has entered into a collaboration and marketing agreement with Radius XR, Inc.
-
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
7/12/2023
Glaukos Corporation plans to release second quarter 2023 financial results after the market close on Wednesday, August 2, 2023.
-
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
6/5/2023
Enrollment Completion Achieved in Less Than Six Months from Trial Commencement, Ahead of Original Timing Expectations.
-
Glaukos Announces Participation in the William Blair Growth Stock Conference - May 24, 2023
5/24/2023
Glaukos Corporation today announced that its management is scheduled to participate in the William Blair 43 rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 10:40 a.m. CT in Chicago, IL.
-
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
5/5/2023
Glaukos Corporation today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for iDose® TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review.
-
Glaukos Announces First Quarter 2023 Financial Results
5/3/2023
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023.
-
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
5/1/2023
Glaukos Corporation announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA.
-
Glaukos Announces the Release of its 2022 Sustainability Report
4/19/2023
Glaukos Corporation today announced that it has published its 2022 Sustainability Report.
-
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
4/12/2023
Glaukos Corporation plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023.